EGFR and neoplasm: The 1D8N/CEGa1 trimerbody may be able to maximize tumor-specific costimulation due to the combination of a higher total tumor uptake and substantially faster circulatory clearance, ultimately giving an improved T/N ratio as compared to conventional IgG-based anti-EGFR and anti-4-1BB antibodies.